Fluorescence Resonance Energy Transfer (FRET) and Proximity Ligation Assays Reveal Functionally Relevant Homo- and Heteromeric Complexes among Hyaluronan Synthases HAS1, HAS2 and HAS3

Genevieve Bart¹, Nuria Ortega Vico², Antti Hassinen², Francois M. Pujol², Ashik Jawahar Deen¹, Aino Ruusala³, Raija H. Tammi¹, Anthony Squire⁴, Paraskevi Heldin³, Sakari Kellokumpu², Markku I. Tammi¹*

¹Institute of Biomedicine/Anatomy, University of Eastern Finland, FI-70211 Kuopio, Finland
²Faculty of Biochemistry and Molecular Medicine, University of Oulu, FI-90014 Oulu, Finland
³Ludwig Institute for Cancer Research, Uppsala University, SE-75124, Uppsala, Sweden
⁴Institute for Experimental Immunology and Imaging, University Clinic Essen, 45147 Essen, Germany

Running title: Homo- and heteromeric complexes of HAS1, HAS2 and HAS3

*To whom correspondence should be addressed: Markku Tammi, Institute of Biomedicine, School of Medicine, University of Eastern Finland, Yliopistonranta 1E, P.O.Box 1627, 70211 Kuopio, Finland. Tel. +358-40-7674826, Fax +358-17-163032, Email tammi@uef.fi

Key words: Hyaluronan, HAS1, HAS2, HAS3, fluorescence resonance energy transfer, proximity ligation assay

Background: Co-immunoprecipitation experiments suggest the existence of HAS2-HAS2 and HAS2-HAS3 enzyme complexes

Results: FRET and proximity ligation assays show homo- and heteromeric complexes among all HASs

Conclusions: Like Golgi glycosyltransferases, HASs form homo- and heteromeric complexes

Significance: Different HAS complexes may have specific effects on hyaluronan synthesis

In vertebrates, hyaluronan is produced in plasma membrane from cytosolic UDP-sugar substrates by HAS1-3 isoenzymes that transfer N-Acetyl glucosamine (GlcNAc) and glucuronic acid (GlcUA) in alternative positions in the growing polysaccharide chain during its simultaneous extrusion into the extracellular space. It has been shown that HAS2 immunoprecipitates contain functional HAS2 homomers and also heteromers with HAS3 (Karousou et al. 2010 J. Biol. Chem. 285 23647-23654). Here we have systematically screened in live cells potential interactions among the HAS isoenzymes using fluorescence resonance energy transfer (FRET) and flow cytometric quantification. We show that all HAS isoenzymes form homomeric and also heteromeric complexes with each other. The same complexes were detected both in Golgi apparatus and plasma membrane by using FRET microscopy and the acceptor photobleaching method. Proximity ligation assays with HAS antibodies confirmed the presence of HAS1-HAS2, HAS2-HAS2, and HAS2-HAS3 complexes between endogenously expressed HASs. C-terminal deletions revealed that the enzymes interact mainly via uncharacterized N-terminal 86 amino acid domain(s), but additional binding site(s) probably exist in their C-terminal parts. Of all homomeric complexes HAS1 had the lowest and HAS3 the highest synthetic activity. Interestingly, HAS1 transfection reduced the synthesis of hyaluronan obtained by HAS2 and HAS3, suggesting functional cooperation between the isoenzymes. These data indicate a general tendency of HAS isoenzymes to form both homomeric and heteromeric complexes with potentially important functional consequences on hyaluronan synthesis.
Hyaluronan is a ubiquitous glycosaminoglycan present in the pericellular and extracellular matrix of most vertebrate tissues. It is a hydrophilic polysaccharide, which tends to form gels even at low concentrations (1). It serves as a space filler, providing elasticity for soft connective tissues, lubrication for synovial joints, transparency for the vitreous body, and extracellular diffusion routes for cellular nutrients and waste products (2). Hyaluronan can also be considered as a kind of cushion, buffering cells from physical and chemical impacts, as reflected by its rapidly increased synthesis in inflammation and tissue injury. Hyaluronan is very abundant during embryonic development, where it is associated with cell migration and proliferation during organogenesis (3). A genetic defect in hyaluronan synthesis leads to a lethal failure in heart development (4). Recent research has also assigned a number of critical signaling functions to hyaluronan, mediated by its cell surface receptors (CD44 and RHAMM) (5-7) and common growth factor receptors like those of ErbB (8), PDGF (9), and TGFβ families (10). There is now considerable interest in the metabolism of hyaluronan as a potential target of therapy in pathological processes such as cancer (11), arterial disease (12), diabetes (13) and various forms of inflammation (14).

Hyaluronan is produced by hyaluronan synthases (HAS1-3 in mammals). These enzymes have two different glycosyltransferase activities in a single polypeptide. Using cytosolic UDP-glucuronic acid and UDP-N-acetylglucosamine as donor substrates (15), they catalyze the transfer of N-acetylglucosamine to glucuronic acid in β1-4 linkage and glucuronic acid in β1-3 linkage to N-acetylglucosamine. This results in alternating positions of these monosaccharides and the formation of a repeated disaccharide structure (-GlcNAc-GlcUA-) in a linear glycosaminoglycan chain, usually of a molecular mass in the range of $10^6$- $10^7$ Da (16). Unlike other vertebrate glycoconjugates, hyaluronan is not known to be built on any protein or lipid core. For the bacterial enzyme (seHAS) the possibility of lipid or protein carriers that could initiate hyaluronan synthesis, has been excluded (17). Moreover, while HAS polypeptides are co-translationally inserted in the ER membrane and transported to the Golgi apparatus, they become activated only after reaching the plasma membrane (18). The mechanisms that turn on hyaluronan synthesis at the plasma membrane, but prevent the premature activation in intracellular membranes, remain obscure. However, substrate supply and HAS localization are dynamically coupled as depletion of UDP-GlcUA (19) or UDP-GlcNAc (20) reduces the amount of HAS in the plasma membrane. Translocation of HAS between the plasma membrane and intracellular membranes involves vesicular trafficking factors like Rab10 (21).

Active hyaluronan synthesis at plasma membrane also requires a pore for simultaneous extrusion of the growing polysaccharide chain into the extracellular space. Streptococcal HAS itself forms the pore together with phospholipids, (17, 22), while this has not been firmly demonstrated for vertebrate HASs. Modulation of MDR transporter activity affects hyaluronan synthesis in mammalian cells, and MDR proteins have been suggested to mediate hyaluronan transport (23). However, the evidence of hyaluronan extrusion through separate transporters has remained circumstantial, and their role has been disputed (24). The fact that hyaluronan is not generally detected in the cytosolic side of the plasma membrane (25), where it should be found if entering a separate extrusion channel, speaks against the existence of a separate pore for hyaluronan export. This is also consistent with the findings that Streptococcal (26) and Xenopus XIHAS1 (27) are active without interaction with other proteins.

Bacterial exopolysaccharide synthesis also involves membrane-associated glycosyltransferases that presumably form a translocation pore for the transfer of their product into the periplasm. For example, the extrusion pore of the poly-β-1,6-N-acetylglucosamine synthesis machinery of Y. pestis (28) and E. coli (29) is suggested to
require the formation of a heterodimer with altogether 6 transmembrane domains. On the other hand, channels such as lactose permease contain 12 transmembrane \( \alpha \)-helices (30), while the two protein subunits of bacterial cellulose synthase contain altogether 9 transmembrane domains, and couple polymerization with membrane penetration (31). The closest relatives of HASs, the insect chitin synthases, contain up to 16 membrane spanning \( \alpha \)-helices, and are likely functional as dimers or oligomers (32).

For HAS enzymes, the previously proposed schematic structures (15) have not considered the possibility of homo- or heteromeric HAS complexes. Indeed, this possibility was raised for the first time in a recent study, in which co-immunoprecipitation experiments demonstrated that HAS2 formed homomeric complexes, and even heteromeric complexes with HAS3 (33). The functional importance of the homomeric interactions of HAS2 was demonstrated when an enzymatically inactive HAS2 mutant showed a dominant negative effect on hyaluronan synthesis when co-transfected with an enzymatically active HAS2 (33). In the present work, we have explored potential homo- and heteromeric interactions among mammalian HAS isoforms in cells in situ using fluorescence resonance energy transfer (FRET) and proximity ligation assays (PLA). The results establish that all 3 human HAS isoforms can interact with each other. The data also suggest that the different HAS isoenzyme combinations expressed in various cells and cellular environments may have specific effects on hyaluronan biosynthesis.

**EXPERIMENTAL PROCEDURES**

**Plasmid constructs for flow cytometry** – The plasmids for flow cytometric FRET analyses were made as follows. The functional open reading frames (ORF) of human hyaluronan synthase genes (Has1, NCBI Nucleotide accession number NM_001523, Has2 (NM_005328 and Has3 (NM_005329) were amplified from human cDNA and first ligated in frame with the pDendra2-C vector (Evrogen, Moscow, Russia). The HAS cDNAs in Dendra2 plasmids were cloned by 25 cycles of PCR with \( pfu \) polymerase (Fermentas INC, Glen Burnie, MD, USA) into either the pcDNA3-Myc-tag vector (HAS1 and HAS3) or into the pcDNA3-HA-tag vector (HAS2) using the HindIII and XhoI restriction sites and the following primers:

5'HAS1-ATTAAAGCTTATGAGACACGAGACCGGCGC, 3'HAS1 ATTACTCAGACCTGGACGCGGTAGC, 
5'HAS2-ATTAAAGCTTATGCATTGTGAGAGGTTTCT ATGTATC, 3'HAS2- ATTACTCAGACCTGGACGCGGTAGC, 
5'HAS3-ATTAAAGCTTATGCCGGTGAGGAGGTCT ATGTATC, 5'HAS3- ATTACTCAGACCTGGACGCGGTAGC, 

All the constructs were sequenced to verify that no mutations had arisen. Primers for pcDNA3 forward and reverse (Fwd-ACGACTCACTATAGGGAGAC, Rev- AATGCTAGAGCTCGCTGATC) were used for the sequencing together with new ones (designed to sequence from about 500 bp inside each gene (HAS1-GGGAGGTGGAGGCC, HAS2- TGCAAAAATGGGGTGG, and HAS3 CGTGCACTATGCAGAAGT) to allow complete sequencing of the constructs. Each HAS cDNA was PCR amplified and the product inserted into the pcDNA3 vector (Clontech Laboratories, Inc., Mountain View, CA, USA) using HindIII and XhoI restriction sites and the sequences verified. The vector also contained sequences encoding a C-terminal 5 amino acid linker region (RSIAT) followed by either the monomeric Cerulean (mCer), monomeric Venus (mVen), HA (YPYDVPDYA) or myc (EQKLISEEDL) tag (34). Thus, the constructs for flow cytometric FRET had the tags in the C-terminus of the HASs.

**Plasmids for the microscopic FRET analyses and co-immunoprecipitations** - EGFP-HAS1 was created by inserting XhoI-EcoRI fragment
from Dendra2-HAS1 plasmid into the pEGFP-C1 vector. The mCherry-HAS1 was created by ligating together mCherry with NheI-BglII, HAS1 BglII-EcoRI and pCI-Neo NheI-EcoRI. The mCherry-Has2 was created by ligating together mCherry NheI-BglII, HAS2 BglII-Sall and pCI-Neo NheI-Sall. The construction of EGFP-HAS2, EGFP-HAS3 and mRFP-HAS3 have been described elsewhere (21). mCherry-HAS3 was created by ligating together mCherry NheI-XhoI, HAS3 XhoI-EcoRI and pCI-Neo with XhoI-EcoRI. C-terminally truncated EGFP-HAS1 (143 residues) was created by digestion of EGFP-HAS1 with Sall followed by re-ligation. C-terminally truncated mCherry-Has3 (220 residues) and EGFP-HAS3 (166 residues) were made by digestion with BamHI and with PstI, respectively, before re-ligation. C-terminally truncated EGFP-HAS3-86 was produced by digesting EGFP-HAS3 with SacII, and re-ligation. N-terminally truncated HAS3 was produced by ligating together HAS3 C-terminus fragment SacII-EcoRI, EGFP-C3 NheI-SacII and PCIneo NheI-EcoRI. The C-terminally mCherry-tagged HAS3 was created by replacing Cerulean with mCherry in pcDNA3-HAS3-Cer in XhoI-NotI restriction sites.

Co-immunoprecipitations – Cos1 cells were co-transfected with EGFP-HAS1, 2 or 3 and mCherry-HAS1 or 2 or mRFP-HAS3 in 1:1 ratio. The efficiency of transfection and presence of both fluorophores in cells were verified by microscopy. 24-30 h after transfection the cells were scraped from the plates and membrane proteins were prepared as in (33), immunoprecipitated using RFP-trap-M (ChromoTek GmbH, Munich, Germany), and eluted from the beads in SDS-PAGE sample buffer (0.125 M Tris-HCl, pH 6.8, with 4% SDS, 20% glycerol, 0.2 M dithiothreitol, and 0.02% bromphenol blue) for 15 min at 65°C. Co-precipitation was tested in western blots with anti-GFP antibody (Invitrogen NY, USA), and imaged with an Odyssey infrared system Licor, Lincoln, NE).

Immunofluorescence microscopy and FRET flow cytometry – COS7, COS1, HeLa, and MCF7 cells were cultivated in DMEM as described earlier (34, 35). One day after plating, the cells were transfected using 0.5 µg of each plasmid cDNA and the FuGENE6™ transfection reagent (Roche Applied Sciences, Basel, Switzerland). After cultivation for 24 h at 37°C or 30°C, the cells were used either for fluorescence microscopy, flow cytometric FRET, or enzyme activity measurements (hyaluronan synthesis). Cells were processed for indirect immunofluorescence as previously described (36). After fixation, the cells were permeabilized with 1 ml of 0.1 % saponin in 1 % BSA-PBS, pH 7.4, and stained with the Golgi marker antibody (anti-GM130 610822, BD Biosciences, San Jose, CA, USA) and Alexa fluor 594 -conjugated secondary antibodies (Invitrogen, Carlsbad, CA, USA). After staining, the cells were imaged using a Zeiss Observer Z1 equipped with a LSM 700 confocal unit, 63 X PlanApo oil immersion objective and appropriate filter sets for CFP, YFP and Alexa 594, and Zen2009 software (Carl Zeiss AG, Oberkochen, Germany).

FRET measurements were done as described (35). Briefly, one day after plating, the cells were transfected with the FRET plasmid constructs that encoded selected enzymes tagged with either the mCer or the mVen. After 24 h, the cells were detached from the plates with 2 x trypsin-EDTA (Sigma-Aldrich), diluted, and analyzed on a flow cytometer (CyFlow, Partec GmbH, Münster, Germany) equipped with appropriate filter sets for mCer (405ex, 425-475em) and mVen (488ex, 515-540em). In each measurement, 2-5 x 10^3 cells expressing both mCer and mVen were selected by gating (for setting and validation of the gates, see (34) and quantified in triplicate from three different experiments (as mCer/mVen ratios). The FRET filter set (405ex, 515-540em) and FloMAX software were used for the quantification. The FRET signal is presented as the percentage of FRET positive cells of those that express both mCer and mVen constructs (FRET+; mean ± SD). A value higher than 5% was considered relevant.
**FRET microscopy** - COS1 cells were routinely cultivated in DMEM High glucose (Invitrogen, Paisley, UK), 10% FBS (HyClone), 2 mM glutamine, 50 mg/ml Penicillin (EuroClone). For experiments, cells were plated on 8-well Ibid chamber slides for 24 h before transfection, 15 000 cells per well. Medium level was adjusted to 200 µl just prior to transfection. Per well, 12.5 µl 150 mM NaCl, 0.1µg DNA (EGFP/mCherry plasmid ratio: 1/1), and 0.5 µl Exgen 500 (Fermentas, Helsinki, Finland) were mixed. The cells were fixed 48 h after transfection in 4% paraformaldehyde for 10 min and washed for 5 min in 50 mM Tris and 100 mM NaCl, pH 8.0, and kept in PBS at 4°C before analyses. A Zeiss LSM700 confocal microscope with Plan-Apochromat 40x/1.3 Oil DIC M27 objective was used. Cells expressing both EGFP- and mCherry-tagged HAS constructs were examined. Images from EGFP (ex 488 nm, em 555 nm short pass filter) and mCherry (ex 555 nm) were taken separately. To measure FRET efficiency, mCherry was photobleached using 555 nm laser at maximum setting for 10 to 30 seconds, and then second pictures of both fluorophores were taken. Images were analyzed using an image processing software package (Fiji) with ImageJ and several other plugins organized into a coherent menu structure. FRET efficiency (E) was calculated for each pixel in the bleached area as follows: 

$$ E = \frac{(I_{\text{Donor post bleach}} - I_{\text{Donor pre bleach}})}{I_{\text{Donor post bleach}}} \times 100. $$

$I_{\text{Donor}} = \text{intensity of EGFP fluorescence}$. The microscopic FRET setup was essentially as described before (37). 

**Proximity ligation assay (PLA)** – Normal human mesothelial cells (AG07086B, NIA aging Cell Culture Repository, Coriell Institute, Camden, USA) were cultured in F12 Ham medium (Sigma) supplemented with 15% FBS, 10 ng/ml human EGF (PeproTech, UK), 0.05 µg/ml hydrocortisone (Sigma), 2 mM L-glutamine and 1% of Penicillin/Streptomycin (Sigma). 20000 cells were seeded/well using 8-well chamber slides (Lab-Tek, Thermo Scientific Nunc) and grown for 3 days. The cells were washed with PBS, fixed in 3% paraformaldehyde for 10 min, permeabilized in 0.25% Triton-X-100 for 5 min, washed with PBS, blocked with 100 mM glycine, and washed again with PBS. In situ PLA was performed at SciLifeLab PLA proteomics facility, Uppsala, Sweden, according to the instructions of the probe manufacturer (Olink Bioscience, Uppsala, Sweden). The cellular background for PLA was visualized by incubation with 0.25 µg/ml of FITC-phalloidin (Sigma) and 4',6-diamidino-2-phenylindole (DAPI). After staining, the cells were examined with a Zeiss AxioPlan2 microscope. For counting the fluorescent dot signals, CellProfiler Broad Institute cell image analysis software was used. The specificity of the signal was controlled by counting the dots produced when one of the primary antibodies was omitted or replaced by preimmune serum. 

The following primary antibodies at a dilution of 1 µg/ml were used for the PLA: rabbit anti-HAS1 antiserum (affinity purified) and pre-immune serum (37), HAS2 goat polyclonal antibody (sc-34067, Santa Cruz), rabbit anti-HAS2 antiserum (affinity purified) and pre-immune serum (38) as well as rabbit anti-HAS3 antiserum (Abcam 322231). 

**Hyaluronan synthesis by the HAS complexes** - COS7 cells were transfected with the appropriate HAS-mCer and -mVen constructs and cultivated 24 h before the collection of growth media from the plates. The media were stored frozen (-20°C) until the hyaluronan assay (see below). The cells were washed and detached from the plates using trypsin-EDTA and analyzed by flow cytometry to determine in each plate the transfection efficiency of HAS-mCer- and -mVen constructs, the mean intensity of the fluorescent tags (a measure of the amount of each enzyme protein present) and the percentage of FRET positive cells per plate. These values were then used to normalize the original raw data values (µg hyaluronan/ml of medium) into corrected values. These were in turn used to calculate the activities of the various complexes relative to that of HAS1 homomer (a set a value of 1). All cell measurements were done using three independent plates. 

Tet-Inducible C8161 EYFP-HAS2 melanoma cells were produced by lentiviral transduction in the same way as in (38). The lentiviral vector was made as follows: the HAS2 coding sequence was isolated from EGFP-HAS2 plasmid cut with XhoI and EcoRI, EYFP from EYFP-C1 with XhoI and NcoI, and ligated with the entry vector pentTTGmirc2 NcoI-EcoRI. The plasmid containing all fragments in frame was recombined into pSLICK-hygromycin (39). The cells were grown in high glucose DMEM, 10% FBS (Hyclone, Logan, UT), 2 mM L-glutamine (Euroclone), 50 µg/ml streptomycin sulfate, and 50 units/ml penicillin, 50 µg/ml hygromycin. The cells were characterized for HA secretion with different doses of doxycycline (0, 0.1, 0.25, 0.5, 1 and 2 µg/ml). In a 96-well plate 5000 C8161-EYFP-HAS2 cells were plated. After 24 h, a medium with 1% FBS was changed, followed by transient transfection with 50 ng/well of HAS1-mCer, HAS3-mCer, HAS3-mVen, or empty mCer (Mock) plasmids with TurboFect transfection reagent (Thermo Scientific), resulting in 50-60% transfection efficiency. 16 h later, the cells were treated with 0.25 µg/ml doxycycline. 24 h later, fluorescence (mCer, mVen and EYFP) from the cells in each group was measured and the media were analyzed for hyaluronan secretion with an enzyme-linked sorbent assay, as described below.

The amount of hyaluronan secreted into the medium was determined using a sandwich type enzyme-linked sorbent assay based on the hyaluronan-binding complex (HABC, containing aggrecan G1 domain and link protein) extracted and purified from calf articular cartilage in our laboratory (40). Briefly, Maxisorb 96-well plates were coated with 1 µg/ml hyaluronan binding complex (HABC), blocked with 1% bovine serum albumin in PBS, incubated with samples and hyaluronan standards, washed and incubated with 2 µg/ml of biotinylated HABC, followed by the streptavidin peroxidase reaction visualized by 3,3’,5,5’-tetramethyl benzidine (41).

Statistical analysis – Student’s t-test, and one way anova followed by Dunnett multiple comparison test, were done with GraphPad Prism5 for Windows (GraphPad Software, La Jolla, CA). Differences were considered significant if P<0.05.

RESULTS

Co-immunoprecipitation of the HAS enzyme complexes - Mouse HAS2 enzyme was shown to form homomeric complexes by co-immunoprecipitation of Flag- and 6myc-labeled HAS2 co-transfected in COS-1 cells. Co-immunoprecipitation was also shown to take place when HAS2 and HAS3 were co-transfected, suggesting the possibility of additional heteromeric HAS complexes (33). In this study we used co-immunoprecipitations to check whether HAS1, like HAS2 and HAS3, could also form homo- and heteromeric complexes. We co-transfected EGFP-, RFP- and mCherry-tagged HASs. Using beads that specifically bind red fluorescent proteins (including mRFP and mCherry), but not EGFP, we found that EGFP-HAS1 at the expected molecular mass of ~90 kDa was brought down by mCherry-HAS1, indicating the presence of homomeric HAS1 complexes (Fig. 1A). In addition, HAS1 heteromeric complexes with either HAS2 or HAS3 were also shown by co-immunoprecipitation with mRFP-HAS3 and mCherry-HAS2 (Fig. 1). EGFP alone was not co-immunoprecipitated with mRFP-HAS3 or mCherry-HAS2, indicating that the fluorescent tags were not responsible for complex formation. A lighter band at 70-80 kDa was also present in the immunoprecipitates, perhaps representing an EGFP-HAS1 that had lost a fragment from its C-terminus, but still able to bind all HAS isoforms. HAS3 tagged with mCherry and RFP also precipitated with EGFP-HAS3, suggesting HAS3 homomerization. The earlier (33) and the present study thus suggest that all HASs can be precipitated in both homo- and heteromeric complexes.

Flow cytometric quantification of FRET in the HAS complexes - Immunoprecipitations require lysis and dissolution of the cells, which
can potentially disrupt and change protein associations, and thus also their interactions. Additional experiments using alternative approaches were therefore done to study the presence of the complexes in situ, without cell disruption, utilizing fluorescence resonance energy transfer (FRET).

We and others have previously shown that mammalian HAS polypeptides with either N-terminal (19, 20, 42) or C-terminal (27, 43) fluorescent tags retain full enzymatic activity, and are mainly detectable in the ER-Golgi area, but also in the plasma membrane. Immunofluorescence microscopy revealed that our new C-terminally tagged HAS enzymes localized predominantly in the Golgi apparatus and plasma membrane (Fig. 2), consistently with previous reports (19, 43).

Quantitation of potential interactions among the different HAS isoenzymes with FRET-flow cytometry revealed both enzyme homomers and heteromers in all the cell lines studied, most of them expressing relatively low levels of endogenous HAS enzymes and thus also low hyaluronan synthesis. About 60-80% of cells expressing HAS1 or HAS3 were FRET positive, indicating the formation of enzyme homomers (Fig. 3A). In contrast, the amount of HAS2 homomers was markedly lower, ranging between 10-20% of the cells. All HAS isoenzymes also formed heteromeric complexes with each other, even though some variation was detected between the different cell types (Fig. 3B). In MCF7 cancer cells, the amount of both homomeric and heteromeric complexes were lowest of the cell types tested.

The specificity of the interactions was confirmed by co-transfecting cells with non-fluorescent HASs to compete with each of the FRET-pairs. HAS1-myc plasmid transfected together with the HAS1-mCer/HAS1-mVen pair reduced the FRET signal to less than 30% of the original, indicating that the interactions are mediated by the HAS1 enzyme itself and not by the fluorescent tags (Fig. 4A). A similar reduction took place when HAS2 or HAS3 homomers were challenged with either HA- or myc-tagged constructs (Fig. 4B and C).

Similar experiments with the different HAS heteromers showed that the FRET signal of each of the complexes was markedly reduced upon co-transfection of the competing Myc- or HA-tagged enzyme construct. In all cases, heteromeric interactions were reduced to 10-30% of the original FRET signal (Fig. 4D-F). Collectively, the data show that the homomeric and heteromeric interactions detected among the different HAS isoenzymes are specific and not mediated by random collisional binding events.

**FRET microscopy** - The HAS proteins are known to be co-translationally inserted in the ER membrane, after which they are transported through the Golgi apparatus to the plasma membrane, where they become enzymatically active (19, 43). Thus, ectopic expression of the GFP-HAS constructs results in their localization in these compartments as well as in endocytic vesicles (Fig. 2) (19, 20, 42, 43). Immunocytochemical detection of endogenously expressed HASs indicates a similar localization pattern (44). The highest amount of HAS polypeptides is generally found in the Golgi apparatus (Fig. 2).

Potential interactions among the different HAS isoenzymes and their location were studied also by FRET microscopy, using N-terminally tagged EGFP and mCherry HAS pairs, and the acceptor photobleaching method. In line with the flow cytometric analyses, significant homo- and heteromeric interactions were detected among all HAS isoenzymes. Heteromeric interactions between HAS1/HAS2, HAS1/HAS3 and HAS2/HAS3 are shown in Fig. 5A. These examples demonstrate measurement polygons placed in the Golgi region where FRET was quantitated by the increase of donor fluorescence after acceptor photobleaching. While plasma membrane contained relatively lower HAS fluorescence, FRET signal was detected also there (Fig. 5A bottom right). The calculated FRET efficiencies for all the homo- and heteromeric complexes are presented in Fig. 5B. The FRET efficiencies were relatively high, as indicated also by the low background.
when EGFP-HAS1 was co-transfected with mCherry alone (Fig. 5B).

**Endogenous HAS enzyme complexes** – To confirm that the endogenous, non-transfected HAS proteins also interact in situ, proximity ligation assays (PLA) were used on mesothelial cells known to express all HAS isoforms. The cells were fixed and labeled with primary antibodies raised in different species, allowing distinct DNA tags in the secondary antibodies. When close enough (<40 nm), the DNA-tags facilitate ligation, amplification, and a fluorescent signal. Microscopic counting of the fluorescent dots formed in the presence of goat and rabbit HAS2 antibodies revealed numerous endogenous HAS2 homomers in the cells (Fig. 6). The combination of goat HAS2 and rabbit HAS1 or HAS3 antibodies revealed also the presence of endogenous heteromeric complexes between HAS1 and HAS2, and HAS2 and HAS3. The numbers of dots detected with these antibody sets clearly exceeded the background level obtained by counting together the signals (dots) of each antibody alone. Pre-immune rabbit sera when combined with the specific goat anti-HAS2 antibody gave also a background signal comparable to that of the antibody alone. These data indicate that endogenously expressed HAS proteins form homomeric and heteromeric complexes, thus excluding the possibility that the complexes arise only when HASs are over-expressed.

**Domains of the HAS polypeptides involved in the interactions** - The FRET observed between the N-terminally tagged HAS constructs indicate that the distance between the N-termini of two HAS proteins is less than 10 nm. Likewise, positive FRET in the C-terminally tagged HASs used for flow cytometry indicate that the C-termini of the HAS complex partners were within 10 nm of each other. Interestingly, FRET was not observed when HAS3, labeled with mCherry in its C-terminus, was co-transfected with EGFP in the N-terminus of HAS1, HAS2, and HAS3 (data not shown). The absence of FRET suggests that the HAS complexes are organized in a manner where the N- and C-termini of the two interacting HASs are beyond 10 nm of each other.

To find out which HAS domains are responsible for the interaction, microscopic FRET was performed with C-terminally truncated HAS1 containing EGFP in the N-terminus. HAS1, missing all the C-terminal transmembrane domains, and part of the cytosolic putative glycosyltransferase domain (truncated at amino acid 143) still interacted with the full length HAS2 that contained mCherry in its N-terminus (Fig. 7A). Likewise, the N-terminal domain of HAS3, truncated at amino acid 166, produced a FRET signal with full length HAS3 and HAS2, and also with HAS3 truncated at amino acid 220 (Fig. 7A). In contrast, HAS1 truncated close to the N-terminus (amino acid 12) was not able to associate with HAS2 (Fig. 7A). These data suggest that a domain for HAS homo- and heteromer formation is located close to the N-terminal part of the enzymes.

The presence of an interacting domain in the N-terminal part of HASs was confirmed by co-immunoprecipitation of full-length mCherry-HAS2 with EGFP-HAS3 C-terminally truncated at amino acid 86 (Fig. 7B). EGFP alone was not precipitated with mCherry-HAS2, indicating specific binding between the HASs (Fig. 7B). The HAS3 construct in which the N-terminus was truncated at amino acid 86 and replaced by EGFP, was also precipitated with HAS2. The latter finding indicates that there is(are) other binding domain(s) between the HAS polypeptides that reside outside of the N-terminal region. Western blots from cells transfected with intact and truncated GFP-HAS3 constructs showed also unidentified smaller bands, partly enriched in, and partly excluded from the immunoprecipitates (Fig. 7B). As above with HAS1 (Fig. 1), these can represent HAS3 that have lost fragments from the C-terminus.

**Hyaluronan synthesis by the enzyme complexes** – To evaluate whether the various HAS enzyme complexes are active and functionally relevant, we measured the ability
of the three HASs, transfected alone and in different combinations, to synthesize and secrete hyaluronan into the extracellular medium.

Fig. 8A shows the normalized relative synthetic activities in the experimental set-up in which flow cytometry was used to measure the fluorescence of mCer and mVen, as described above. While the synthesis was normalized to fluorescence (the level of HAS protein), the findings were similar without normalization (data not shown). The activity of HAS1 alone was found to be lowest and was therefore used as a reference value. In the COS7 cells used in these experiments HAS2 and HAS3 had a 40-fold and 80-fold, respectively, higher activity than HAS1. Intriguingly, the highest activity was detected with the HAS2-HAS3 combination, ~2x higher than the sum of the two transfected alone. In contrast, the HAS1-HAS3 combination did not significantly increase hyaluronan synthesis relative to the HAS3 alone, while HAS1 and HAS2 co-expression showed markedly lower synthesis than HAS2 alone.

Hyaluronan synthesis by the different HAS combinations was also studied on a C8161 melanoma cell line in which we introduced stable expression of doxycycline-inducible EYFP-HAS2. The induced expression of EYFP-HAS2 was studied with and without transient HAS1-mVen and HAS3-mCer transfections. The induction-controlled expression of HAS2 reduced the variation in hyaluronan synthesis and increased the precision of the assays. These results confirmed the finding that introduction of HAS1 suppressed hyaluronan synthesis by HAS2, but its influence on hyaluronan synthesis by HAS3 was also inhibitory (Fig. 8B). In these cells and this experimental set-up, hyaluronan synthesis by the HAS2-HAS3 combination was not additive, but showed values close to HAS3 alone. Nevertheless, the data suggest that the different HAS isoforms have the potential to modulate hyaluronan synthesis by the other isoforms, suggesting cooperative functioning in hyaluronan synthesis through heteromerization.

DISCUSSION

The present work shows for the first time in situ complexes between HAS polypeptides in several cell types. These findings are in line with a previous report showing homomeric interactions between HAS2, and heteromeric interactions between HAS2 and HAS3 in vitro (33). The present data also indicate that all three HAS isoenzymes can form homo- and heteromeric complexes in live cells. Moreover, the PLA data show that this is also the case for endogenous HAS enzymes, thereby excluding the possibility that complex formation is merely a result of enzyme overexpression in the cells. These findings open completely novel vistas on the structure-function relationship of HASs.

The data is interesting in the light of a recent report on Golgi-localized glycosyltransferases involved in the processing of N- and O-linked oligosaccharides. These glycosyltransferases have also been shown to form both homomeric and heteromeric complexes in situ (35). In this particular case, heteromerization was found to take place only between sequentially acting enzymes. HAS enzymes, despite being active only at the plasma membrane, share the same tendency to form homo- and heteromers. Recent studies have also demonstrated homo- and heteromeric complexes between cell wall-synthesizing enzymes, i.e. chitin, cellulose and poly-β-1,6-N-acetylglucosamine synthases (29, 31, 32). These enzymes resemble HASs in that they are also thought to form a pore in plasma membrane for extrusion of the growing polysaccharide chain. Altogether, our findings emphasize that complex formation might be a general property of perhaps all glycosyltransferases, and that they function as larger units, rather than as enzyme monomers as previously thought. Whether the complexes represent dimeric, tetrameric or even higher oligomeric structures, remains unclear at the moment. However, there are some indications
that tetramers and even higher oligomers are involved. For example, digitonin-solubilized HAS1, fractionated on a gel filtration column, shows enzymatically active HAS1 at very high molecular mass (~600 kDa) (45). A part of solubilized SeHAS also elutes in a position corresponding to a dimer (17). The Golgi-localized GalT1 and ST6Gal1 transferase activities and proteins elute as a size of enzyme tetramers (34) but large oligomers have also been reported (46). Further structural studies are necessary to resolve the exact composition of the HAS homomers and heteromers.

The C-terminal truncation experiments indicated that one of the sites mediating the homo- and heteromeric binding was located between their N-termini and the glycosyltransferase domains of the interacting HAS proteins. However, truncation of this N-terminal part still allowed binding, indicating that additional binding site(s) exist also outside of this domain, closer to the C-termini. More information about the interacting domains comes from the FRET signals, which were positive between the N-termini or the C-termini, but negative between the N- and C-termini of the binding partners. This suggests that the interaction precludes close proximity of the C- and N-termini of the interacting proteins.

The observed homo- and heteromerization among the different HAS isoenzymes introduces a number of important questions concerning their formation, trafficking and physiological relevance in hyaluronan synthesis. For example, we showed that all the complexes had strong FRET signals in the perinuclear Golgi region, and less at the cell surface. This may be due to the predominant localization of the HAS polypeptides in the Golgi region and the relatively weaker signal at the plasma membrane. The data suggest that complex formation does not take place upon enzyme activation and initiation of hyaluronan synthesis, which presumably occur at the plasma membrane, but rather, already in the ER or the Golgi. Complex formation may however be a prerequisite for activation at the cell surface by other factors, or it may be necessary for HAS trafficking to the plasma membrane (21).

It is possible that the complexes are dynamic and freely interchangeable with each other. This would provide rapid means to modulate either the activity or trafficking of the complexes in response to physiological demands. This would be analogous with the formation of Golgi glycosyltransferase heteromers, in contrast to homomers, upon lowering the pH of Golgi lumen (34).

Complex formation raises also interesting possibilities concerning the function of the HAS isoenzymes in hyaluronan synthesis. Firstly, earlier data (33) suggests that the complexes are required for HAS activity, as co-transfection of a mutated, non-functional HAS2 inhibits hyaluronan synthesis by an intact HAS2, in a dominant negative manner. We also showed that introduction of HAS1 reduced the synthesis of hyaluronan by HAS2 and HAS3, suggesting that HAS1 heteromers are less active than HAS2-HAS2 and HAS3-HAS3 homomers.

However, in the present experiments, coupling the levels of hyaluronan synthesis to distinct HAS complexes should be regarded only as suggestive, as it is based on the assumption that the ratios and levels of co-transfected and overexpressed HAS isoenzymes mimic those that exist between endogenous HAS proteins. This may not be the case in each physiological condition, or in every cell type in vivo, given the variable expression of HASs in different cell types (20, 47). In addition, the normalization of the hyaluronan synthesis to the amount (fluorescence intensity) of HAS protein may not correlate with the amount of active protein, part of which may have undergone denaturation or fragmentation. Since truncated HASs are also able to form complexes, they could potentially influence the enzymatic activity of native HAS proteins, perhaps in a dominant negative manner (33). It is also obvious that at any time point only a relatively small part of total cellular HAS
resides in the plasma membrane, the site of HA synthesis.

The exact proportions of the HASs in complexes vs. monomers are not known, although the robust FRET signals suggest that the homo- and heteromers are common, if not the dominant form. Therefore, factors other than complex formation can also contribute to the observed changes in hyaluronan synthesis by the different HAS isoforms. Obviously, analyses of the association/dissociation constants between HASs, and their consequences in hyaluronan synthesis rate, are needed.

The expression levels of the different HASs are known to be highly dynamic. A stimulus often increases the expression of two (48), or all three HASs (47, 49). The inductions of the HAS isoforms occur at different time points following a stimulus, last for different periods of time, and are mediated by different signaling pathways (49). The sequential HAS inductions are expected to create temporal changes in the stoichiometry between the HAS proteins, which can influence the rate of hyaluronan synthesis, as suggested by the present data. However, potential functions affected by the cooperation between HASs, besides synthesis rate, also include the molecular mass of the hyaluronan, and the way it is organized on cell surface (20, 50).

An interesting corollary to the homo- and heteromeric organization of the HASs is that this arrangement might allow sequential addition of GlcNAc and GlcUA by separate HAS polypeptides complexed with each other. This would solve the dilemma how a single, relatively small protein with two transferase activities, and binding tightly to hyaluronan, could allow hyaluronan extrusion through a pore made by the enzyme itself. It can be speculated that processive rachet-like shifting of the growing polymer between the UDP-GlcNAc and UDP-GlcUA binding sites (15) could involve sites on separate but interacting HAS polypeptides, resembling the model suggested recently for SeHAS (17). A larger pore through complex formation can also be envisioned to better accommodate hyaluronan extrusion. These and other possibilities warrant further exploration of the HAS protein quaternary structures and their functional consequences.
REFERENCES


pathways involves pH-dependent complex formation that is impaired in cancer cells. *J.Biol.Chem.* **286**, 38329-38340


mediated by p38 and Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) signaling. *J. Biol. Chem.* **288**, 17999-18012


**FOOTNOTES**

**Acknowledgements** – We thank Ms Riikka Kärnä for skillful technical assistance. This work was financially supported by the Academy of Finland (SK, MT), Sigrid Juselius Foundation (MT, RT), The National Glycoscience Graduate School (AD, SK, MT), Kuopio University Hospital (EVO/VTR funds) (MT), The University of Eastern Finland Spearhead Funds (Cancer Center of Eastern Finland) (MT, RT), Magnus Ehrnrooth Foundation (AH) and Finnish Cultural Foundation (AH), the Ludwig Institute for Cancer Research (PH) and the Swedish Cancer Society (PH). Personal grants to AD from Northern Savo Cultural Foundation, Northern Savo Cancer Funds, and CIMO are gratefully acknowledged.

**Abbreviations used** - HAS, hyaluronan synthase; FRET, fluorescence resonance energy transfer; EGFP, enhanced green fluorescent protein; mCer (or ECFP) monomeric Cerulean (Cyan) fluorescent protein; mVen (or EYFP), monomeric Venus (Enhanced Yellow) fluorescent protein; mCherry, monomeric Cherry fluorescent protein.

**Legends to the figures**

**Figure 1.** Co-immunoprecipitations of HAS isoforms. (A) HAS1 Co-immunoprecipitations with HAS1, HAS2 and HAS3. Beads that bind mRFP and mCherry were used to immunoprecipitate mRFP-HAS3, mCherry-HAS2 and mCherry-HAS1 from COS-1 cultures co-transfected with EGFP-HAS1. (B) HAS3-HAS3 co-immunoprecipitations. COS1 cells were transfected with either mCherryHAS3 and EGFP-HAS3 or mRFP-HAS3 and EGFP-HAS3 and immunoprecipitated as in (A). The presence of co-transfected EGFP-HAS1 (A) and EGFP-HAS3 (B) in the precipitates was analyzed by western blotting using an anti-GFP-antibody. An EGFP plasmid without insert was used as a negative control, see left lane in (A). The calculated molecular masses of EGFP-HAS1, EGFP-HAS2 and EGFP3 are 92, 90 and 90 kDa, respectively.

**Figure 2.** Subcellular distribution and co-localization of HAS1, HAS2 and HAS3 with C-terminal mVen and mCer tags. COS7 cells were transfected with the indicated constructs, fixed 24 h later, and stained with an antibody against the Golgi marker GM 130 (red). Arrowheads point to cell surface.

**Figure 3.** Quantitation of the FRET signals by flow cytometry with mVen and mCer constructs in COS1, COS7, HeLa, and MCF7 cells. The cells expressing both mVen and mCer were analyzed by flow cytometry for FRET-positive cells (% of counted) in triplicate, counting 100-300 cells in each measurement. Homomeric complexes are shown in panel (A) and heteromeric complexes in (B). Means ± SD are shown.
Figure 4. Inhibition of FRET signal by FRET-incompatible HAS constructs. The left column in each panel shows the FRET % of the indicated HAS pair in COS7 cells. The right columns indicate the corresponding FRET % (Mean ± SD, n= 3) in the presence of competing HAS-myc or HAS-HA constructs.

Figure 5. FRET microscopy determined by donor fluorescence increase after acceptor photobleaching. N-terminal EGFP and mCherry tagged HAS constructs were co-transfected in COS-1 cells and imaged with confocal microscopy. (A) Examples of heteromeric interactions between HAS1/HAS2, HAS1/HAS3, and HAS2/HAS3. Emission of EGFP (green) before and after photobleaching of mCherry (red) is shown in photobleached regions of interest (marked by the red line). Differential interference contrast (DIC) images of the cells are shown between those of EGFP and mCherry. The rightmost panels show false color scaling of FRET efficiency. (B) For each measurement a FRET efficiency was calculated from the pre- and post-donor fluorescence intensities in the photobleached Golgi area as demonstrated by the red regions of interest in (A). The average FRET efficiency of each HAS combination is expressed as the mean ± SE from 10-18 cells expressing both EGFP and mCherry. FRET efficiencies were calculated for all homo- and heteromeric HAS complexes (HAS1/1; HAS2/2; HAS3/3; HAS1/2; HAS1/3; HAS2/3). EGFP-HAS1 with an empty mCherry vector is indicated by HAS1/0 and was used as a negative control. The FRET efficiencies of all HAS pairs were found to be significantly different from the FRET efficiency calculated for the negative control (HAS1/0) (P<0.05, One way analysis of variance with Dunnett's post hoc test).

Figure 6. Interactions detected by proximity ligation assay (PLA) between endogenous HAS1, HAS2 and HAS3 in mesothelial cells. Pairs of goat and rabbit antibodies against HASs, detected by DNA-labeled secondary antibodies, were ligated together when the proteins were close enough to interact, and amplified into a fluorescent dot. The numbers of dots obtained by replacing the rabbit HAS1 and HAS2 antibodies with their respective preimmune sera, or by omitting one of the antibodies, represent the background signal. The micrographs show an example of the HAS2/HAS2 signal and its control with preimmune serum. The columns show means ± SE of 5-11 images from 2 experiments. ***P<0.0005, **P<0.005, *P<0.01, compared to the corresponding pair with preimmune serum (Wilcoxon-Mann-Whitney Rank sum Test).

Figure 7. Homomeric and heteromeric interactions with truncated HAS constructs. (A) The full length and C-terminally truncated HAS1 and HAS3 constructs subjected to microscopic FRET are schematically illustrated on top. The larger horizontal boxes represent the putative cytosolic glycosyltransferase domains, while the small boxes indicate predicted transmembrane or membrane-associated domains. The transfected HAS combinations are indicated under the columns, the truncated ones marked by the number of their amino acids. Means±SE of 7-15 determinations are shown. The difference in the FRET efficiency of HAS3/HAS3 vs. HAS3-166 aa/HAS3 220 aa was statistically significant (p<0.05, analysis of variance with Dunnett’s post hoc test) (B) Full length HAS3 and its N- and C-terminally truncated constructs schematically illustrated on top were co-transfected with mCherry-HAS2. The complexes were precipitated with the RFP-trap-M for red fluorescent proteins and analyzed by SDS-PAGE in reducing conditions, followed by western blotting using a GFP antibody to show the co-precipitated HAS3 constructs. Total cell lysates and the immunoprecipitates are shown in the left and right blots, respectively. The empty EGFP vector (left lanes) was used as a control (present in the lysate but not in the
immunoprecipitate). The predicted molecular masses of intact EGFP-HAS3, -86aa EGFP-HAS3, 86aa EGFP-HAS3, and EGFP are 90, 80, 37 and 27 kDa, respectively.

**Figure. 8.** Hyaluronan synthesis by the different HAS complexes. (A). HAS-mCer and -mVen were in transfected to COS7 cells and cultivated for 24 h after which the media were collected for the determination of hyaluronan levels. The cells were detached and analyzed for fluorescence by flow cytometry to allow calculation of the normalized, relative activities of the various HAS complexes, as described in the “Experimental Procedures”. Each column represents the corrected values (Mean ± SD) from triplicate samples. HAS1 activity (=1) was used as a reference value. (B) C8161 cells were stably transduced with EYFP-HAS2 gene, the expression of which could be induced by doxycyclin (Dox). The cells were transiently transfected with mCer or mVen with or without EYFP-HAS2 induction, using 0.25 µg/ml Dox. The hyaluronan values were normalized to the mCer fluorescence of the cultures. The EYFP, mCer and mVen fluorescence ratios in each of the pairs ranged between 0.70 and 1.15, suggesting roughly equal expressions of the constructs. Means ± SE of three separate experiments are shown. The decrease in the hyaluronan synthesis of HAS2 and HAS3 by co-transfection of HAS1 was statistically significant, P<0.05 and P<0.001, respectively, using repeated measures ANOVA, with Bonferroni corrections.
IP: mRFP or mCherry -> Western blot: EGFP
Fig. 2

Cos7 37°C 24h

HAS1-Cer +HAS1-Ven

HAS2-Cer +HAS2-Ven

HAS3-Cer +HAS3-Ven

HAS1-Cer +HAS2-Ven

HAS1-Cer +HAS3-Ven

HAS2-Cer +HAS3-Ven

10 µm
Fig. 3

(A) FRET positivity (%) for HAS1, HAS2, and HAS3 in COS1, COS7, HeLa, and MCF7 cells.

(B) FRET positivity (%) for combinations of HAS1+HAS2, HAS1+HAS3, and HAS2+HAS3 in COS1, COS7, HeLa, and MCF7 cells.

Downloaded from http://www.jbc.org/ at VIVA, Univ of Virginia on April 30, 2015
Fig. 4

A

FRET (% of cells)

HAS1/1  HAS1/1
+HAS1-myc

B

FRET (% of cells)

HAS2/2  HAS2/2
+HAS2-HA

C

FRET (% of cells)

HAS3/3  HAS3/3
+HAS3-myc

D

FRET (% of cells)

HAS1/2  HAS1/2
+HAS2-HA

E

FRET (% of cells)

HAS1/3  HAS1/3+
HAS1-myc  HAS1/3+
HAS3-myc

F

FRET (% of cells)

HAS2/3  HAS2/3
+HAS2-HA
Fig. 5

A

<table>
<thead>
<tr>
<th>EGFP-HAS1</th>
<th>DIC</th>
<th>mCherry-HAS2</th>
<th>FRET efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EGFP-HAS1</th>
<th>DIC</th>
<th>mCherry-HAS3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td></td>
<td></td>
</tr>
<tr>
<td>After</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EGFP-HAS2</th>
<th>DIC</th>
<th>mCherry-HAS3</th>
<th>FRET efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

FRET efficiency (%)

HAS combination

1/0 1/1 2/2 3/3 1/2 1/3 2/3

10 μm 5 μm 15%
Fig. 6

HAS2/HAS2 (goat/rabbit)

HAS2/preimm.HAS2 (goat/rabbit)

HAS2/HAS2 (goat/rabbit)

HAS2/preimm.HAS2 (goat/rabbit)
Fig. 8

A

Hyaluronan (ng/ml, corr. for Cer+Ven)

HAS1  HAS2  HAS3  HAS1-2  HAS1-3  HAS2-3

B

Hyaluronan (ng/ml, corr. for Cer)

Control  HAS1  HAS2  HAS3  HAS1-2  HAS1-3  HAS2-3
Glycobiology and Extracellular Matrices: Fluorescence Resonance Energy Transfer (FRET) and Proximity Ligation Assays Reveal Functionally Relevant Homo- and Heteromeric Complexes among Hyaluronan Synthases HAS1, HAS2 and HAS3

Genevieve Bart, Nuria Ortega Vico, Antti Hassinen, Francois M. Pujol, Ashik Jawahar Deen, Aino Ruusala, Raija H. Tammi, Anthony Squire, Paraskevi Heldin, Sakari Kellokumpu and Markku I. Tammi

_J. Biol. Chem. published online March 20, 2015_

Access the most updated version of this article at doi: [10.1074/jbc.M115.640581](http://doi.org/10.1074/jbc.M115.640581)

Find articles, minireviews, Reflections and Classics on similar topics on the JBC Affinity Sites.

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 0 references, 0 of which can be accessed free at [http://www.jbc.org/content/early/2015/03/20/jbc.M115.640581.full.html#ref-list-1](http://www.jbc.org/content/early/2015/03/20/jbc.M115.640581.full.html#ref-list-1)